This Article Full Text Full Text (PDF) Erratum (v23,p656) Erratum (v23,p656) Erratum (v22,p4435) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ajani, J.A. Articles by Gunderson, L.L. Search for Related Content PubMed PubMed Citation Articles by Ajani, J.A. Articles by Gunderson, L.L. Social Bookmarking                            What's this?

Multi-Institutional Trial of Preoperative Chemoradiotherapy in Patients With Potentially Resectable Gastric Carcinoma

From The University of Texas M.D. Anderson Cancer Center, Houston, TX; Washington University, St Louis, MO; and Mayo Clinic, Scottsdale, AZ

Address reprint requests to Jaffer A. Ajani, MD, Department of Gastrointestinal Medical Oncology, Stop 426, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030; e-mail: jajani{at}mdanderson.org

PURPOSE: In the West, curative (R0) resection is achieved in approximately 50% of patients with localized gastric carcinoma, and more than 60% die of cancer following an R0 resection. A multi-institutional study of preoperative chemoradiotherapy was done to assess the R0 resection rate, pathologic complete response (pathCR) rate, safety, and survival in patients with resectable gastric carcinoma.

PATIENTS AND METHODS: Operable patients with localized gastric adenocarcinoma were eligible. Staging also included a laparoscopy and endoscopic ultrasonography (EUS). Patients received up to two 28-day cycles of induction chemotherapy of fluorouracil, leucovorin, and cisplatin, followed by 45 Gy of radiation plus concurrent fluorouracil. Patients were then staged and surgery was attempted.

RESULTS: Thirty-four patients were registered at three institutions. One ineligible patient was excluded. Most patients had a promixal cancer and EUST3N1 designation. Twenty-eight (85%) of 33 patients underwent surgery. The R0 resection rate was 70% and pathCR rate was 30%. A pathologic partial response (< 10% residual carcinoma in the primary) occurred in eight patients (24%). EUS T plus N and postsurgery T plus N correlation showed significant downstaging (P = < .01). The median survival time for 33 patients was 33.7 months. Patients achieving a pathCR or pathPR had a significantly longer median survival time (63.9 months) than those achieving less than pathPR (12.6 months; P = .03). There were two treatment-related deaths.

CONCLUSION: Our data suggest that the three-step strategy of preoperative induction chemotherapy followed by chemoradiotherapy resulted in substantial pathologic response that resulted in durable survival time. This strategy is worthy of a direct comparison with postoperative adjuvant chemoradiotherapy.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. FUJITANI, T. TSUJINAKA, H. YAMASAKI, M. HIRAO, K. YOSHIDA, and Y. KUROKAWA Feasibility Study of S-1 plus Weekly Docetaxel Combined with Concurrent Radiotherapy in Advanced Gastric Cancer Refractory to First-line Chemotherapy Anticancer Res, August 1, 2009; 29(8): 3385 - 3391. [Abstract] [Full Text] [PDF]

				N. I. Khushalani Cancer of the Esophagus and Stomach Mayo Clin. Proc., June 1, 2008; 83(6): 712 - 722. [Abstract] [Full Text] [PDF]

				L Rubbia-Brandt, E Giostra, C Brezault, A. Roth, A Andres, V Audard, P Sartoretti, B Dousset, P. Majno, O Soubrane, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery Ann. Onc., February 1, 2007; 18(2): 299 - 304. [Abstract] [Full Text] [PDF]

				J. A. Ajani, K. Winter, G. S. Okawara, J. H. Donohue, P. W.T. Pisters, C. H. Crane, J. F. Greskovich, P. R. Anne, J. D. Bradley, C. Willett, et al. Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response J. Clin. Oncol., August 20, 2006; 24(24): 3953 - 3958. [Abstract] [Full Text] [PDF]

				L. Lim, M. Michael, G. B. Mann, and T. Leong Adjuvant Therapy in Gastric Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232. [Abstract] [Full Text] [PDF]

				O. Bouche, M. Ychou, P. Burtin, L. Bedenne, M. Ducreux, G. Lebreton, J. Baulieux, B. Nordlinger, C. Martin, J. F. Seitz, et al. Adjuvant chemotherapy with 5-fluorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801) Ann. Onc., September 1, 2005; 16(9): 1488 - 1497. [Abstract] [Full Text] [PDF]

				C. Kollmannsberger, W. Budach, M. Stahl, N. Schleucher, T. Hehr, H. Wilke, J. Schleicher, U. Vanhoefer, E. C. Jehle, K. Oechsle, et al. Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO Ann. Onc., August 1, 2005; 16(8): 1326 - 1333. [Abstract] [Full Text] [PDF]

				E. P.M. Jansen, H. Boot, M. Verheij, and C. J.H. van de Velde Optimal Locoregional Treatment in Gastric Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4509 - 4517. [Abstract] [Full Text] [PDF]

				A. S. Allal Preoperative Radiochemotherapy in Gastric Cancer: Another Ongoing Shift From Adjuvant to Neoadjuvant? J. Clin. Oncol., June 1, 2005; 23(16): 3870 - 3870. [Full Text] [PDF]

				J. A. Ajani In Reply: J. Clin. Oncol., June 1, 2005; 23(16): 3870 - 3871. [Full Text] [PDF]

				J.A. Ajani, P.F. Mansfield, C.H. Crane, T.T. Wu, S. Lunagomez, P.M. Lynch, N. Janjan, B. Feig, J. Faust, J.C. Yao, et al. Paclitaxel-Based Chemoradiotherapy in Localized Gastric Carcinoma: Degree of Pathologic Response and Not Clinical Parameters Dictated Patient Outcome J. Clin. Oncol., February 20, 2005; 23(6): 1237 - 1244. [Abstract] [Full Text] [PDF]